美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.69

-0.4365-1.24%

盤後：34.720.0307+0.09%16:15 EDT

成交量：2.55萬

成交額：88.51萬

市值：9,643.63萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.14

換手率：0.92%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯

华夏时报网

信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂

ETF日報(09.10)丨臨床風險事件擾動等多因素疊加，創新藥板塊回落銀行股温和普漲

翰宇藥業(300199.SZ)：HY3003注射液臨床試驗申請獲受理

翰宇藥業：HY3003注射液獲臨床試驗申請受理通知書

又爆了！集體飆漲！中東，再傳重磅

東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點

創新藥概念股震盪調整，百普賽斯跌超10%，萬邦醫藥、百花醫藥、千金藥業、博濟醫藥、諾思格跌超5%。

中信證券：創新藥出海漸入佳境，板塊進入盈利拐點

英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准

石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

安進（AMGN）聯合療法III期臨床達主要終點

【券商聚焦】中郵證券維持翰森製藥（03692）買入評級指創新藥成增長核心

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBBQ/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.6893,"timestamp":1789761600000,"preClose":35.1258,"halted":0,"volume":25482,"hourTrading":{"tag":"盘后","latestPrice":34.72,"preClose":34.6893,"latestTime":"16:15 EDT","volume":9,"amount":312.326514,"timestamp":1789762500328,"change":0.0307,"changeRate":0.000885,"amplitude":0.000885},"delay":0,"changeRate":-0.012426763233862154,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":-0.4365,"latestTime":"09-18 17:02:57 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":885086,"amplitude":0.014246,"askPrice":47.09,"askSize":100,"bidPrice":32.86,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":34.34966,"aum":95492089.14966,"dividendRate":0.007406,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.72,"preClose":34.6893,"latestTime":"16:15 EDT","volume":9,"amount":312.326514,"timestamp":1789762500328,"change":0.0307,"changeRate":0.000885,"amplitude":0.000885},"volumeRatio":1.139227,"impliedVol":0.0457,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.139227,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.6893,"committee":0.333333,"eps":0,"divideRate":0.007406,"volume":25482,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666560028","title":"2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560028","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:12","pubTimestamp":1789038763,"startTime":"0","endTime":"0","summary":"9月9日正午，北京西黄城根北街2号全国人大会议中心。最后一家参与商保创新药目录价格协商的企业代表走出大门，历时五天的2026年国家医保目录现场谈判竞价与商保创新药目录价格协商正式收官。新版国家基本医保药品目录与商保创新药目录预计今年11月公布，2027年1月1日起统一执行。五天时间里，124个目录外药品先后完成基本医保谈判竞价，12个创新药冲击商保创新药目录价格协商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870706515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870706515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","IBBQ","BK1161","MEDX","LNGR","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666648561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面，信立泰转型取得阶段性成果的同时，核心产品收入集中的风险始终悬而未决。作为转型最重要的产品，信立坦2024 年销售额约 15 亿元，是公司创新药板块最主要的收入来源，公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保，形成产品梯队，但是这些新产品体量尚小，短期内难以替代信立坦的收入贡献，公司仍然处于单品依赖阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","LNGR","BK0196","002294","MEDX","REDS","BK0028","KCE","BK1574","BK0188","IBBQ","BK1161","FRHC","159992","BK4127","BK0187","BK0239","BK0183","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666693435","title":"ETF日報(09.10)丨臨床風險事件擾動等多因素疊加，創新藥板塊回落 銀行股温和普漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2666693435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666693435?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:43","pubTimestamp":1789029788,"startTime":"0","endTime":"0","summary":"临床风险事件扰动等多因素叠加，创新药板块集体回落；定增政策红利释放、中报验证盈利韧性，银行板块温和普涨。行业表现临床风险事件扰动、海外利率预期反复与资金风格轮动三重因素叠加，创新药板块集体回落。截至收盘，恒生创新药ETF华泰柏瑞跌2.93%，报1.356元；港股通创新药ETF工银跌2.67%，报1.132元；港股创新药ETF广发跌2.65%，报1.251元。截至收盘，银行AH优选ETF招商涨1.65%，报1.603元；银行ETF汇添富涨1.56%，报1.5元；银行ETF华夏涨1.39%，报1.829元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","159992","PY","ROPE","EQRR","BK1574","BK1161","VALQ","FDN","IBBQ","TALV","SPVM","LNGR","CGVV","BK4585","VUSV","VLUE","DFLV","06978","VMAX","VTV","SWP","ABEQ","MEDX","PRF","BK4588","BKDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566579","title":"翰宇藥業(300199.SZ)：HY3003注射液臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566579?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:21","pubTimestamp":1789028518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司于近日收到国家药品监督管理局核准签发关于HY3003注射液临床试验申请的《受理通知书》。该项目通过人工智能结合多肽芯片技术筛选得到新型多肽分子，由翰宇药业负责临床前研究、IND申报及后续临床试验开发。HY3003拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。HY3003项目是翰宇药业与碳云智肽在“AI+多肽”领域深度合作的典范。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","300199","BK0070","IBBJ","BK0239","MDTX","BMED","IBBQ","BK0077","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666565044","title":"翰宇藥業：HY3003注射液獲臨床試驗申請受理通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2666565044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666565044?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:12","pubTimestamp":1789027978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","BMED","IBBQ","PSYK","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528665","title":"又爆了！集體飆漲！中東，再傳重磅","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528665","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528665?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:37","pubTimestamp":1789011420,"startTime":"0","endTime":"0","summary":"中午好，在本周二大涨之后，能化板块又爆发了！周四早盘，原油期货主力合约一度涨近10%，纯苯、苯乙烯期货主力合约涨停。截至11:30收盘，原油期货主力合约涨幅有所收窄，纯苯期货主力合约涨 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4599","LU1571399168.USD","LU0868494617.USD","LU1983299246.USD","LU0058720904.USD","IBBQ","LU0109394709.USD","LU0289739699.SGD","LU2242652126.USD","LU2468319806.SGD","LU0320765992.SGD","LU2089984988.USD","BK4139","LU1057294990.SGD","BBH","IE0002141913.USD","LU2112291526.USD","TBXU","BK4588","IE0009355771.USD","LU0122379950.USD","AMGN","LU0889565916.HKD","BK4585","LU2242646821.SGD","BK4534","IE00BJJMRZ35.SGD","PJP","SG9999001440.SGD","PBE","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4533","IE00BJT1NW94.SGD","BIB","IBB","LU1023059063.AUD","BK4581","BK4566","LU1061106388.HKD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666513175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK1574","159992","BK0028","06978","MEDX","000686","LNGR","CXO","BK0276","BK1161","WX","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666746559","title":"創新藥概念股震盪調整，百普賽斯跌超10%，萬邦醫藥、百花醫藥、千金藥業、博濟醫藥、諾思格跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666746559","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666746559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:49","pubTimestamp":1789004940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555207","title":"中信證券：創新藥出海漸入佳境，板塊進入盈利拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555207","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555207?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:24","pubTimestamp":1788999885,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555270","title":"英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555270?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:20","pubTimestamp":1788999632,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，公司管线中领先的AI驱动候选创新药物 Rentosertib，已于北京协和医院完成III期临床试验的首例患者入组及给药;同日，上海市肺科医院亦完成了其在该试验的首例患者入组。GENESIS-IPF-3为一项评估Rentosertib用于特发性肺纤维化患者的III期临床试验。本试验旨在评估Rentosertib是否能比IIa期研究提供涵盖更大患者群体、且更长时间治疗的临床意义上的获益。Rentosertib透过抑制TNIK，旨在阻断或逆转纤维化进程，为IPF患者提供具备疾病改善潜力的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GPIQ","NJAN","03696","TQQY","CHAT","CPNQ","IBBJ","QID","MVPS","QQQ","PSQ","GK","ARTY","VUSE","TARK","AIFD","BMED","TQQQ","AIQU","AGIX","OGIG","FWD","159992","QQA","NOCT","PBOT","KOMP","QSWN","MEDX","MDTX","NEWZ","TECY","DQJN","QTOC","MFIG","IBBQ","06978","PSYK","NJUL","161631","QMAR","QQQX","CWC","AQGX","NBDS","WPAI","LCLG","LNGR","AIBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HK0000165453.HKD","LU1992135399.USD","BK1574","LU2272731600.USD","LU2322448791.USD","PPH","HK0000320264.USD","LNGR","LU2473716301.USD","LU2272731782.SGD","LU2272731865.HKD","IE00B5TLWC47.USD","XPH","06978","MEDX","IBBQ","HK0000306701.USD","IBB","HK0000320223.HKD","BK4588","159992","BK4585","LU1992135472.HKD","02696","LU2322448957.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533226","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:54","pubTimestamp":1788958467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731782.SGD","IBBQ","LU1992135472.HKD","IBB","LU2322448957.HKD","XPH","LNGR","LU2272731600.USD","LU2272731865.HKD","PPH","BK4585","LU1992135399.USD","LU2322448791.USD","IE00B5TLWC47.USD","BK4588","LU2473716301.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580156","title":"拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580156?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954150,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","IBBJ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666846135","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666846135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666846135?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:09","pubTimestamp":1788948562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","LU2039709279.SGD","LU0314109678.HKD","LU1328277881.USD","MDTX","LU0501845795.SGD","IBBQ","IE0008368742.USD","KURE","IE00B543WZ88.USD","LU1226288170.HKD","BMED","LU0067412154.USD","LU1960683339.HKD","LU0140636845.USD","LU0326950275.SGD","IBBJ","01093","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU1226287529.USD","LU1813983027.USD","LU1951186391.HKD","PSYK","LU0315179316.USD","IE00B5MMRT66.SGD","BK1191","LU0072913022.USD","BK1515","IE0008369823.USD","LU1008478684.HKD","BK1521","LU1152091168.USD","LU1226288253.USD","LU1226287875.USD","LU1993786604.SGD","LU1152091754.HKD","LU1226287792.SGD","SG9999004220.SGD","LU1807302812.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584690","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584690?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，该集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0072913022.USD","HK0000165453.HKD","KURE","LU0140636845.USD","LU1951186391.HKD","LU1807302812.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","BMED","LU1008478684.HKD","LU1226288170.HKD","IE00B5MMRT66.SGD","IBBQ","LU0315179316.USD","LU0326950275.SGD","BK1521","LU1328277881.USD","LU1152091754.HKD","IE0008368742.USD","BK1191","IE00B031HY20.USD","IE00BZ08YT58.USD","LU1813983027.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU2039709279.SGD","BK1515","LU1152091168.USD","SG9999004220.SGD","IBBJ","01093","IE00B543WZ88.USD","LU0501845795.SGD","LU1226287875.USD","PSYK","LU1226288253.USD","MDTX","LU1226287529.USD","LU0314109678.HKD","LU1226287792.SGD","LU0880133367.SGD","IE0008369823.USD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666845175","title":"石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次","url":"https://stock-news.laohu8.com/highlight/detail?id=2666845175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666845175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBJ","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666898185","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666898185","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666898185?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","MDTX","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589136","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589136","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589136?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944940,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月9日，百利天恒公告称，公司自主研发的全球首创双抗ADC宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。每日经济新闻 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IBBJ","MDTX","688506","BK0239","BMED","IBBQ","PSYK","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU0432979614.USD","BIB","IE00BJJMRZ35.SGD","LU2237443622.USD","PJP","LU2456880835.USD","LU2462157665.USD","LU0128525929.USD","BK4533","AMGN","BK4581","PBE","LU1267930573.SGD","TBXU","IE00B4R5TH58.HKD","SG9999001440.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU0889565916.HKD","LU1023059063.AUD","LU2089984988.USD","AZN","BK4139","AZNH","LU1829250122.USD","LU0708994859.HKD","LU2242652126.USD","LU2112291526.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU2237443895.HKD","LU2468319806.SGD","BK4599","LU2237443978.SGD","BK4534","IBBQ","BK4566","LU0029864427.USD","BBH","BK4585","LU0289739699.SGD","LU1571399168.USD","LU2236285917.USD","LU2237443382.USD","LU0109394709.USD","BK4568","LU0058720904.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458356","title":"【券商聚焦】中郵證券維持翰森製藥（03692）買入評級 指創新藥成增長核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458356","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:32","pubTimestamp":1788939161,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，翰森制药 发布2026年中报，2026H1实现收入83.04亿元，同比增长11.7%；归母净利润42.58亿元，同比增长35.8%，利润高增部分得益于约6.31亿元的投资收益等一次性项目。创新药已成为公司增长的绝对核心。创新药收入达70.92亿元，同比增长15.4%，占总收入比重由去年同期的82.7%提升至85.4%。其中抗肿瘤领域收入54.73亿元，占总收入65.9%；非肿瘤领域收入28.31亿元，占总收入34.1%。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991138","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","IBBQ","159992","MEDX","06978","KCE","LNGR","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":7,"totalSize":215,"code":"91000000","status":"200"}]}}